Proprotein convertase subtilisin/kexin type 9: an update on the cardiovascular outcome studies.

European Heart Journal Supplements : Journal of the European Society of Cardiology
N FerriM Ruscica

Abstract

Inhibitors of the 3-hydroxy-3-methylglutaryl coenzyme A reductase enzyme, statins, are powerful cholesterol-lowering medications and have provided outstanding contributions to the primary and secondary prevention of coronary heart disease. Low-density lipoprotein cholesterol (LDL-C) is one of the major modifiable cardiovascular risk factors, indeed, every 1.0 mmol/L (38.7 mg/dL) reduction in LDL cholesterolaemia corresponds to a 21% lowering in the risk of major vascular events. In this context, the pharmacological approach with PCSK9 monoclonal antibodies is considered a promising non-statin therapeutic option for the management of lipid disorders in patients with persistent cardiovascular risk, including patients with diabetes mellitus. Data from two large clinical trials have indisputably demonstrated the efficacy of alirocumab and evolocumab in preventive major adverse cardiovascular events in high risk, secondary-prevention patients with clinical manifestation of atherosclerotic cardiovascular diseases. Finally, PCSK9 monoclonal antibodies did not increase the risk of serious adverse events, neurocognitive events, new-onset of diabetes, muscle-related events, or myalgia.

References

May 20, 2011·Nature·Peter LibbyGöran K Hansson
Aug 2, 2014·Journal of the American College of Cardiology·S Matthijs BoekholdtJohn J P Kastelein
Jun 4, 2015·The New England Journal of Medicine·Christopher P CannonUNKNOWN IMPROVE-IT Investigators
Mar 26, 2016·Atherosclerosis·Jin M ChengK Martijn Akkerhuis
Mar 18, 2017·The New England Journal of Medicine·Marc S SabatineUNKNOWN FOURIER Steering Committee and Investigators
May 5, 2017·Journal of the American Heart Association·Massimiliano RuscicaUNKNOWN Brisighella Heart Study Group
May 30, 2017·Expert Opinion on Biological Therapy·Nicola FerriMassimiliano Ruscica
Feb 6, 2018·Scientific Reports·Chiara RicciNicola Ferri
Feb 24, 2018·Journal of the American College of Cardiology·Marina CameraNicola Ferri
Nov 8, 2018·The New England Journal of Medicine·Gregory G SchwartzUNKNOWN ODYSSEY OUTCOMES Committees and Investigators
Dec 14, 2018·Journal of the American College of Cardiology·Paolo PoggioMarina Camera

❮ Previous
Next ❯

Citations

Mar 12, 2021·Current Atherosclerosis Reports·Massimiliano RuscicaAlberto Corsini

❮ Previous
Next ❯

Software Mentioned

IT
FOURIER

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.